TARGET PharmaSolutions enroll first patient in IBD Community

TARGET PharmaSolutions has just announced the enrollment of the first participant in its Inflammatory Bowel Disease (IBD) community. This community will include adult and pediatric patients with ulcerative colitis, Crohn's disease, and indeterminate colitis. This is the first step in moving towards creating a bio-repository stakeholders can access for translational studies.